Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.58 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019383 | 0.88 | ADORA2A (0.52) | ADORA2AADORA1PDE7AHTT | |
| SCHEMBL179279 | 0.81 | ADORA2A (0.44) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL24170309 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL19261286 | 0.80 | ADORA2A (0.42) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL8363046 | 0.80 | ADORA2A (0.42) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL18701478 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL14090722 | 0.80 | ADORA2A (0.49) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL11988229 | 0.77 | HTT (0.58) | ADORA2AADORA1PDE7AHTTAXL | |
| SCHEMBL13660429 | 0.77 | ADORA2A (0.54) | ADORA2AADORA1PDE7AADORA3ADORA2B | |
| SCHEMBL24943614 | 0.77 | ADORA2A (0.54) | ADORA2AADORA1PDE7AHTTAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | KYN THERAPEUTICS (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190002442-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373960-A1 | INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | ADORA2A 1376/4885ADORA1 2095/4885PDE7A 4069/4885 |
| US-10570138-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-20190002442-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF | ROCK1, RHOA, ROCK2 | ADORA2A 3025/4885ADORA1 3254/4885PDE7A 162/4885 |
| US-11358969-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-20200331917-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-10689388-B1 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-20240025902-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE | EGFR, ERBB2, CBL | ADORA2A 4273/4885ADORA1 4640/4885PDE7A 4229/4885 |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA2A 3008/4885ADORA1 4194/4885PDE7A 1120/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ADORA2A 330/4885ADORA1 575/4885PDE7A 1966/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA2A 3008/4885ADORA1 4194/4885PDE7A 1120/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ADORA2A 3184/4885ADORA1 2891/4885PDE7A 162/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | ADORA2A 2362/4885ADORA1 3082/4885PDE7A 1056/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | ADORA2A 3008/4885ADORA1 4194/4885PDE7A 1120/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ADORA2A 3184/4885ADORA1 2891/4885PDE7A 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.